Načítá se...
An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years
New molecular mechanisms that can be targeted with specific drugs have recently emerged for the treatment of systemic sclerosis (SSc) patients. Over the past 3 years, the achievement of one large phase 3 trial has led to the approval by drug agencies of the first drug licenced for SSc-related inters...
Uloženo v:
| Vydáno v: | Arthritis Res Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8168022/ https://ncbi.nlm.nih.gov/pubmed/34074331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-021-02536-5 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|